News und Analysen

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its

You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Other than running out of money, what economic risk do Intellia Therapeutics, (NASDAQ: NTLA) CRISPR Therapeutics, (NASDAQ: CRSP) Bluebird Bio, (NASDAQ: BLUE) and a bunch of other cutting-edge

It's best not to go all in on high-risk stocks, but that doesn't mean you should avoid them entirely. If you can tolerate some risk, certain players could make a good addition to a diversified

Shares of Scilex (NASDAQ: SCLX) were down more than 14% as of 1 p.m. ET on Monday, despite the company announcing positive phase 2 trial results for its non-opioid pain therapy SP-103. The healthcar

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

A notable price target cut from an analyst was followed by a dip in the price of DexCom (NASDAQ: DXCM) stock on Friday. Investors traded out of the specialty medical device maker, reducing its value

A notable price target cut from an analyst was followed by a dip in the price of DexCom (NASDAQ: DXCM) stock on Friday. Investors traded out of the specialty medical device maker, reducing its value

Shares of ImmunityBio (NASDAQ: IBRX) were up more than 30% for the week as of 10 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a

Healthcare stocks, often considered recession-proof, have lagged most other sectors of the market so far this year. While the S&P 500 index is up by more than 16% and flirting with a return to bull

Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. It has a diverse business with four key segments: established pharmaceuticals, diagnostics, nutrition, and